Aug 2026· Applied Biosciences· Vol 5, pp. 69· 0 citations· 216 references
TL;DR
This review provides an overview of recent findings on curcumin-based nanocarriers for AD therapy and identifies nanocarrier-based delivery systems as a promising strategy for enhancing the bioavailability and therapeutic efficacy of curcumin.
Abstract
Globally, over 55 million people are affected by Alzheimer’s disease (AD), a number that is increasing rapidly and projected to triple by 2050. AD is a type of neurodegenerative disorder for which there is no curative treatment. The accumulation of amyloid-β (Aβ) plaques and the formation of neurofibrillary tangles are the hallmarks of AD. Curcumin, a bioactive compound extracted from turmeric rhizomes, has shown significant neuroprotective properties, including anti-amyloidogenic, anti-inflammatory, antioxidant, and metal-chelating. Though much research has revealed the potential of curcumin as a promising therapeutic agent for AD, the limited bioavailability of curcumin restricts its effectiveness in pharmaceutical applications. To overcome this challenge, nanocarrier-based delivery systems have emerged as a promising strategy for enhancing the bioavailability and therapeutic efficacy of curcumin. This review provides an overview of recent findings on curcumin-based nanocarriers for AD therapy.
The article aims to examine and discuss the performance and limitations of four NP formulations from different studies, finding polymer-based NPs modified with targeting peptides delivering rifampicin were found to be effective against Aβ accumulation in vivo.
Xi-Ran Wang· American Journal of Student...· 0 citations
Background and Objectives: The main neurodegenerative diseases (NDs)—Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS)—represent a growing global health burden with no available disease-modifying therapies. Curcumin, a polyphenol from Curcuma longa, is...
Alejandra Castelló-Guillen, Marta Garrido-Reig, Jordi Caplliure-Llopis et al.· Pharmaceuticals· 0 citations
Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Current clinical treatments for AD primarily focus on alleviating symptoms but still face limitations such as suboptimal efficacy, side effects, and irreversible neuronal loss. Misfolding of the Aβ peptide plays a key role in AD pathogenesis and prog...
Xiaohua Fang, Zhuo-Bin Zhang, Xiao-Yu Hu et al.· RSC Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
